<DOC>
	<DOCNO>NCT00717587</DOCNO>
	<brief_summary>RATIONALE : Sunitinib may stop growth tumor cell block enzymes need cell growth block blood flow tumor . Giving sunitinib surgery may make tumor small reduce amount normal tissue need remove . Giving surgery may kill tumor cell remain surgery . PURPOSE : This phase II trial study well sunitinib work give surgery treat patient stage IV kidney cancer .</brief_summary>
	<brief_title>Sunitinib Before After Surgery Treating Patients With Stage IV Kidney Cancer</brief_title>
	<detailed_description>OBJECTIVES : - To correlate histologic measure tumor angiogenesis VHL mutation/methylation status clinical outcome patient stage IV renal cell carcinoma treat sunitinib malate . - To determine effect sunitinib malate tumor vascular permeability dynamic contrast-enhanced MRI iodine I 124 chimeric monoclonal antibody G250 positron emission tomography ( PET ) 2 week therapy . - To correlate steady-state plasma concentration sunitinib malate angiogenic growth factor serum clinical outcome patient . OUTLINE : - Neoadjuvant therapy : Patients receive oral sunitinib malate daily day 1-14 . - Cytoreductive surgery : Patients undergo cytoreductive nephrectomy day 16 . - Adjuvant therapy : Beginning least 4 week surgery , patient receive oral sunitinib malate daily day 1-28 . Treatment repeat every 42 day absence disease progression unacceptable toxicity . Patients undergo dynamic contrast-enhanced MRI motexafin gadolinium positron emission tomography iodine I 124 chimeric monoclonal antibody G250 baseline completion neoadjuvant sunitinib malate ( prior cytoreductive nephrectomy ) . Patients undergo tumor tissue blood sample collection periodically correlative laboratory study . Tumor tissue sample analyze VHL mutation somatic genetic mutation mutation analysis ; allelic loss gain comparative genomic amplification ; microvessel density ( MVD ) immunohistochemical stain CD34 CD105 ; pERK , SMA , Ki-67 , HIF-1α , CAIX , macrophage migration inhibition factor ( MIF ) , CREB multicolor analysis ; VEGF-R1 -R2 relevant antigen expression validate assay . Blood sample analyze pharmacokinetics ; angiogenic growth factor level ( e.g. , free VEGF , basic FGF , marker ) ; polymorphism VEGF , VEGFR , VHL , HIF . After completion study treatment , patient follow periodically .</detailed_description>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<mesh_term>Motexafin gadolinium</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis renal cell carcinoma AJCC stage IV disease Radiographic evidence disease cytoreductive nephrectomy deem clinically indicate AND preoperative embolization deem necessary surgeon No history clinical evidence brain metastasis PATIENT CHARACTERISTICS : ECOG performance status 01 WBC ≥ 3,000/mm³ Absolute granulocyte count ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ Serum creatinine ≤ 2.0 time upper limit normal ( ULN ) OR serum creatinine clearance ≥ 40 mL/min Total bilirubin ≤ 1.5 time ULN ( &lt; 3.0 time ULN presence Gilbert 's disease ) AST/ALT ≤ 2.5 time ULN ( ≤ 5.0 time ULN presence liver metastasis ) INR ≤ 1.5* PTT normal* Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No preexisting thyroid abnormality thyroidstimulating hormone maintain normal range medication No hypertension control medication ( i.e. , diastolic BP ≥ 100 mm Hg despite optimal medical therapy ) No ongoing cardiac dysrhythmias ≥ grade 2 ( accord NCI CTCAE v3.0 ) No concurrent malignancies No concurrent serious illness include , limited , follow : Ongoing active infection require parenteral antibiotic Clinically significant cardiovascular disease ( e.g. , uncontrolled hypertension , myocardial infarction , unstable angina ) New York Heart Association class IIIV congestive heart failure Serious cardiac arrhythmia require medication Peripheral vascular disease ≥ grade 2 within past year Psychiatric illness/social situation would limit compliance study requirement NOTE : *Patients take warfarin must documentation INR ≤ 1.5 PTT normal prior initiation anticoagulation rule baseline coagulopathy PRIOR CONCURRENT THERAPY : At least 2 week since prior radiotherapy recover Prior radiotherapy symptomatic site metastatic disease allow No prior systemic therapy No concurrent cytochrome P450 enzymeinducing antiepileptic drug ( e.g. , phenytoin , carbamazepine , phenobarbital ) , rifampin , Hypericum perforatum ( St. John 's wort ) No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>stage IV renal cell cancer</keyword>
	<keyword>recurrent renal cell cancer</keyword>
</DOC>